drugset / Trial / NCT04413617
TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Dual objectives of increased efficacy compared to currently available SoC RA drugs and maintaining a favourable benefit - risk relationship.
Timeline
- Start
- 2020-07-29
- Primary completion
- 2022-02-07
- Completion
- 2022-02-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ritlecitinib | Small molecule | 100 mg | — |
| Subject | Tofacitinib | Small molecule | 11 mg | — |
| Subject | ZIMLOVISERTIB | Small molecule | 400 mg | — |